Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

High-dose biologic delivery to become industry standard

As more drugs go subcutaneous, Phillips Medisize's Tony Bedford believes that high-dose biologics will become a prevalent choice for drugmakers.

Latest news

US set to officially exit WHO in culmination of Trump’s domestic push

A spokesperson for the US Department of State told Pharmaceutical Technology that the “American people have paid more than enough” to the WHO.

BMS bets on Janux’s novel solid tumour therapy through $850m deal

This deal marks another addition to BMS’s growing pipeline, which the company hopes will stave off the impacts of the upcoming patent cliff.

Corxel raises $287m as obesity continues to spark investor interest

Corxel’s lead candidate, CX11, is currently in a Phase II trial in the US and a Phase III trial in China.

Daiichi Sankyo and AstraZeneca’s Enhertu gains NMPA approval for HER2 GEJ

The approval is supported by data from the DESTINY-Gastric04 Phase III trial.

The new safety mandate driving AI-ready pharmacovigilance

Deepanshu Saini, Director of Program Management at IQVIA reflects on the interplay between safety and AI pharmacovigilance.